Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

SHR7390

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Jiangsu Hengrui Pharma

Drug class:

MEK1 inhibitor, MEK2 inhibitor

Related drugs:

MSI-L/dMMR	Colorectal Cancer	MSI-L/dMMR	Colorectal Cancer	camrelizumab + SHR7390 Sensitive: C3 – Early Trials camrelizumab + SHR7390 Sensitive : C3	camrelizumab + SHR7390 Sensitive: C3 – Early Trials camrelizumab + SHR7390 Sensitive : C3
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	camrelizumab + SHR7390 Sensitive: C3 – Early Trials camrelizumab + SHR7390 Sensitive : C3	camrelizumab + SHR7390 Sensitive: C3 – Early Trials camrelizumab + SHR7390 Sensitive : C3
BRAF mutation + MSI-L/dMMR	Colorectal Cancer	BRAF mutation + MSI-L/dMMR	Colorectal Cancer	camrelizumab + SHR7390 Sensitive: C3 – Early Trials camrelizumab + SHR7390 Sensitive : C3	camrelizumab + SHR7390 Sensitive: C3 – Early Trials camrelizumab + SHR7390 Sensitive : C3